|
|
IIR PTI
|
|
| Intermediate level Adverse Event Reporting & Pharmacovigilance |
|
|
|
|
|
|
| |
|
 |
|
|
|
|
| |
Thu 15 Apr 2010
- Fri 16 Apr 2010
Venue to be confirmed, London, England
|
|
|
|
COMPLETELY UPDATED FOR 2009!
The growing awareness of the size and severity of adverse drug reactions, especially with the global use of medicines, has highlighted the need to streamline adverse event reporting and get the right information in the right format as quickly as possible. This advanced-level course will provide decision- makers with the training and knowledge essential to cope with the demands of pharmacovigilance. Packed full with practical exercises and case studies, there can be no better way to ensure that you and your colleagues act competently and confidently throughout the drug safety process.
|
| |
|
Excellent , concise course covering all important areas
Senior DS Physician, ROCHE
|
|
| |
|
Who Will Attend?
Pharmaceutical,Biotechnology and Medical Devices companies, especially within the fields of: • Regulatory Affairs • Pharmacovigilance • Drug Safety • Product Safety • Drug Surveillance • Medical Information • Post-Marketing Surveillance • Medical Affairs • Clinical Safety • Data Management
|
Course Leader
Julie Morrisroe, Director of Innoco Ltd., has spent over 10 years in the pharmaceutical industry in a variety of pharmacovigilance and training roles. Julie has held management roles in both clinical and post marketing pharmacovigilance within corporate and affiliate drug safety units. She has particular expertise in the design, development and delivery of pharmacovigilance and clinical training programs, pharmacovigilance procedure and system design and documentation, safety agreement development, due diligence and pharmacovigilance audits and inspections.
Before joining the pharmaceutical industry Julie practiced as a registered nurse for almost 10 years in a variety of clinical, management and educational positions.
Julie has a degree in Zoology and postgraduate diplomas in pharmacovigilance and health care ethics.
|
|
|
|
|
|
|
|
|